In preclinical models, even at low doses, DNP improved hepatic steatosis, lowered fasting glucose and insulin levels, and reduced triacylglycerol content in liver, plasma, and skeletal muscle in high-fat-fed rats [60]. This evidence concerns the gene INS and fatty liver disease.